Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization

Barailler, H.; Milpied, B.; Chauvel, Annick; Claraz, Pauline; Taı̈eb, Alain; Sénéschal, Julien; Darrigade, Anne‐Sophie

doi:10.1016/j.jaip.2018.04.041

Cited by 10 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 Regarding short protocols, Perez-Sanchez et al reported a desensitization protocol for immediate-type hypersensitivity over 7 days. 8 Although Barailler et al reported a shorter protocol lasting 4 days, 9 hypersensitivity was not confirmed. For delayed-type hypersensitivity, protocols lasting >4 weeks have shown successful desensitization.…”

Section: Successful Short Desensitization For the Eruption Of Hydroxymentioning

confidence: 99%

See 1 more Smart Citation

Successful short desensitization for the eruption of hydroxychloroquine

Hayami

Tanaka

Fujimoto

2019

Lupus

View full text Add to dashboard Cite

Section: Successful Short Desensitization For the Eruption Of Hydroxymentioning

confidence: 99%

“…8 Although Barailler et al. reported a shorter protocol lasting 4 days, 9 hypersensitivity was not confirmed. For delayed-type hypersensitivity, protocols lasting >4 weeks have shown successful desensitization.…”

mentioning

confidence: 99%

Successful short desensitization for the eruption of hydroxychloroquine

Hayami

Tanaka

Fujimoto

2019

Lupus

View full text Add to dashboard Cite

“…DPT is useful in nonsevere cutaneous ADRs in order to differentiate allergic reactions from dermatological adverse effects since only 30% of the patients reporting cutaneous ADRs reveal a positive DPT 90 . Successful desensitization protocols of hydroxychloroquine in MPE were reported 104‐107 . Recently, a 5‐hour desensitization protocol for nonimmediate urticaria was successfully administered 108 (Table 2).…”

Section: Antiviral And/or Immunomodulatory Drugs Used For Viral Pneummentioning

confidence: 99%

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Gelincik

Brockow

Çelik

et al. 2020

Allergy

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID‐19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID‐19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off‐label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off‐label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

show abstract

“…DPT is useful in non-severe cutaneous ADRs in order to differentiate allergic reactions from dermatological adverse effects since only 30% of the patients reporting cutaneous ADRs reveal a positive DPT (87). Successful desensitization protocols of hydroxychloroquine in MPE were reported (101)(102)(103)(104). Recently, a 5-hour desensitization protocol for non-immediate urticaria was successfully administered (105).…”

Section: Hypersensitivity Reactionsmentioning

confidence: 99%

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19

Gelincik

Brockow

Çelik

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.

show abstract

Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization

Cited by 10 publications

References 9 publications

Successful short desensitization for the eruption of hydroxychloroquine

Successful short desensitization for the eruption of hydroxychloroquine

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper

Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19

Contact Info

Product

Resources

About